Press Releases
Neuro-Oncology DIPG-31 Prognostic and predictive biomarkers for H3K27M-altered diffuse intrinsic pontine glioma from PNOC003
Diffuse intrinsic pontine glioma (DIPG) is a fatal brain tumor. Herein, we report on novel prognostic and predictive genomic biomarkers identified in PNOC003, a multi-center precision medicine trial for children and young adults diagnosed with DIPG.
International Journal of Cancer A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from PNOC
This clinical trial evaluated whether whole exome sequencing (WES) and RNA sequencing (RNAseq) of paired normal and tumor tissues could be incorporated into a personalized treatment plan for newly diagnosed patients (<25 years of age) with diffuse intrinsic pontine glioma (DIPG).
DIPG-76 PNOC-003: trial for children with diffuse intrinsic pontine glioma: preliminary experience with multi-agent personalized therapy recommendations
New therapies for children with diffuse intrinsic pontine glioma (DIPG) are greatly needed.